The purpose of the study was to evaluate the feasibility and safety of two cycles of high-dose chemotherapy (HDT) followed by autologous hematopoietic SCT (HSCT) in patients with poor prognosis Ewing family of tumors (EFT). Twenty patients with primary metastatic bulky disease or recurrent EFT were enrolled to a treatment protocol with two cycles of HDT and HSCT. Patients tolerated well the first (n ¼ 20) and second (n ¼ 13) cycles, with limited and predictable toxicities. Only one (5%) TRM occurred during the second cycle. Myeloid engraftment occurred at the median of 11 days after both cycles. At 3 years, the overall and EFS were 45% (confidence interval; CI 0.22, 0.69) and 47% (CI 0.25, 0.70), respectively, for the entire group and 58% (CI 0.30, 0.86) for patients who completed two cycles. Dose intensification with two cycles of HDT and HSCT is feasible and safe, with low and acceptable treatmentrelated morbidity and mortality. Adding a second course of therapy does not impair engraftment. However, only 65% of the patients were able to proceed to the second cycle. Further studies are required to define the optimal mode of delivery of HDT and HSCT in treatment of advanced EFT.
Introduction
The Ewing family of tumors (EFT) includes Ewing's sarcoma (ES), a highly malignant primary bone tumor, and peripheral neuro-ectodermal tumor, neuroepithelioma, Askin's tumor and soft tissue tumors. EFT occurs most frequently in the second decade of life and accounts for 4% of overall childhood and adolescent malignancies. EFT also comprises about 16% of primary malignant bone tumors (American Cancer Society, Key Statistics for Bone Cancer). In recent decades, dramatic improvements in survival in children and adolescents with EFT have been achieved owing to multimodal therapy that incorporates surgery, chemotherapy and/or radiation therapy. More than 65% of patients with nonmetastatic disease have a long-term survival rate. [1] [2] [3] [4] However, patients with bulky primary tumors, with multifocal or metastatic disease at presentation or with refractory or recurrent disease have a very poor prognosis, with only 10-30% survival rate at 3 years. [1] [2] [3] [4] As some studies have shown that there is a positive linear relationship between the dose of cytoreductive agents and tumor response, 5 the approach of high-dose chemo-and/or radiation therapy followed by autologous hematopoietic SCT (HSCT) has been used in the practice of treatment of EFT in an attempt to improve the disease outcome and overall survival (OS) rate. We report our experience with further intensification of treatment in children and adolescents with high-risk EFT. Between 1 January 1997 and 31 December 2003, we treated twenty patients with poor prognosis EFT with an intention to deliver two cycles of high-dose therapy, each followed by autologous HSCT rescue. In this retrospectively designed study, our intention was to analyze the feasibility of treatment, risk of recurrence, EFS and OS.
Patients and methods
From 1 January 1997 to 31 December 2003, 20 patients with high-risk EFT were treated with the intention of delivering two cycles of high-dose chemotherapy (HDT) and HSCT. Eligibility criteria included: histologically proven diagnosis of EFT with metastatic bulky disease at the time of diagnosis or recurrent disease; age less than 35 years old at the date of transplant; Karnofsky performance status of 470% in patients older than 16 years of age, and Lansky's performance status of X70% in children, left ventricular ejection fraction 450% and normal liver and kidney function. All patients were treated with HDT followed by autologous HSCT at City of Hope National Medical Center (COH). There were five female patients and 15 male patients with a median age of 16.24 years at transplant (range: 6.48-29.93 years). A summary of the patients' demographic data as well as clinical course is presented in Table 1 . Six patients had primary advanced disease (PAD) with multiorgan metastatic disease or bulky disease at the time of diagnosis. Bulky disease was defined as a diameter of the primary tumor of X8 cm in the largest cross section. Of the six patients with PAD, four patients had multiple metastases involving more than one organ. Fourteen patients had recurrent disease and 4 of 20 patients had marrow metastases; two had brain metastases; six had lung metastases; two had soft tissue metastases and two patients had bone metastases.
Supportive care
Supportive care was given according to the institutional guidelines. These included the following elements:
Antimicrobial coverage: sulfamethoxazole/trimetoprim was started on admission and given through day À3 for all patients and all cycles. Low-dose acyclovir 250 mg/m 2 /dose, twice a day was given starting day À1 through day þ 30. For prevention of fungal infection, low doses of amphotericin 0.1 mg/kg/dose or amphotericin lipid complex 1 mg/kg/ dose from day À1 through day þ 30 were used. Prompt broad-spectrum antimicrobial coverage was initiated at the temperature of X38.4 1C. Filgrastim (G-CSF) at 5 mg/kg/ day was started on day þ 5.
Statistical analysis
The time of study was defined as the time entry to the study since the first BMT until patients were censored to death. The collected data were analyzed using SAS Software (SAS Institute Inc. Cary, NC, USA). Standard parametric techniques such as frequency tables and univariate analysis were used to describe the patients' demographic and clinical characteristics. The probabilities of survival rate at fixed time points in the study population and subgroups were estimated using Kaplan-Meier methods with the corresponding 95% confidence intervals (CIs). The comparisons of survival curves were made using log-rank test.
Results
Between January 1997 and December 2003, 20 patients were enrolled in the study. All 20 patients completed successfully cycle HDT no. 1 followed by autologous HSCT. Thirteen patients were able to complete the second cycle of the planned treatment.
Treatment
High-dose chemotherapy (first cycle). During the period of the study, two combinations of high-dose therapy have been used for the first cycle. melphalan (Mel) was the main alkylating agent for the first cycle in all patients, coupled with either BU (n ¼ 11, 55%) or carboplatin (n ¼ 9, 45%). The responses to the first cycle of HDT no.1 and HSCT are summarized in Table 2 . Thirteen patients (65%) achieved CR after the first course; one had a partial response (PR), two had stable disease and four had progressive disease.
The various treatment schemas for the first HDT and details of the various treatment schedules are shown in Figure 1 and Table 3 .
High-dose chemotherapy (second cycle). Thirteen patients (65%) were able to proceed with the second cycle of HAD þ HSCT. Three patients declined further therapy, two patients suffered progressive disease, one patient had renal failure (grade 4 renal toxicity) and one had rapidly progressive pulmonary failure with pulmonary fibrosis (grade 4 pulmonary toxicity). One of these seven patients, a 35-year-old man with renal toxicity, is alive with PR and multiple further recurrences of 10 years post transplant. Details of the HDT regimens used for the second cycle are depicted in Table 3 . Of the 13 patients who were able to proceed with a second cycle, eight were treated with a Melcontaining regimen. Mel/carboplatin was given as the second cycle in five patients and Mel/BU in three patients. Five were treated with a combination of CY/VP-16/ carboplatin. Of the 13 patients who proceeded with the second cycle of HSCT, eight are alive and all had achieved a CR after the first HSCT cycle. A summary of the responses and current status is shown in Table 2 .
Toxicity
All patients had experienced, as expected, severe grade 3 or 4 mucositis and grade 4 hematological toxicities. The treatment was otherwise well tolerated by most of the patients. One patient died from multimicrobial, bacterial and viral regimen-related infections and another patient had grade 3 staphylococcus coagulase-negative infections. One patient had renal failure grade 4 due to renal tubular acidosis. There were no grade 3 or 4 cardiac toxicities. There were no cases of veno-occlusive disease. Overall, grade 3-5 toxicities are presented in Table 4 . Engraftment Engraftment occurred uneventfully after both cycles of HDT and HSCT. After the first cycle, a sustained ANC of more than 500/mm 3 and of more than 1000/mm 3 were each achieved at a median of 11 days (range: 9-13 days and 10-14 days, respectively) in all 20 patients. Platelet engraftment, defined as a platelet count of more than 20 000/mm 3 , was documented in 17 evaluable patients at a median of 17 days (range: 10-30 days). In all 13 patients who have received the second cycle of HDT and HSCT, myeloid engraftment with a sustained ANC of more than 500/mm 3 and of more than 1000/mm 3 were each achieved at a median of 11 days (range: 9-13 days and 10-13 days, respectively). A sustained platelet count of more than 20 000/mm 3 for 11 evaluable patients was achieved at the median of 18 days (range: 10-27 days).
Overall survival and EFS
Four of the six patients with primary disease at the time of diagnosis are alive and well with no evidence of disease; two patients died of progressive disease 19 and 8 months, respectively, after the first HSCT. Among 14 patients with recurrent disease, five (35.7%) are alive, four with no evidence of disease and one had more chemotherapy after Tandem autotransplant form Ewing's sarcoma J Rosenthal et al recurrence of disease and is alive with PR 7 years after the completion of a single course of HDT/HSCT. With a median follow-up of 2.4 years, 9 of 20 (45%) patients are alive and 11 (55%) patients had died. Ten patients had metastases at the time of initial diagnosis. Four of these died owing to disease progression and one had died owing to pulmonary fibrosis secondary to influenza type B viral infection; five patients are alive. For the entire group, the probability and 95% CI for OS at 1 year and 3 years were 0.60 (0.36, 0.78) and 0.45 (CI 0.22-0.69), respectively. The estimated probability and 95% CI for EFS at 1 year and 3 years were 0.45 (0.23, 0.65) and 0.47 (CI 0.25-0.70), respectively.
In patients who completed only one cycle of HDT with HSCT, the probability and 95% CI for OS at 1 year were 0.43 (0.10, 0.73) compared to 0.69 (0.37, 0.87) in patients Figure 1 Overall survival and EFS in patients who completed one cycle and patients who completed both cycles.
Tandem autotransplant form Ewing's sarcoma J Rosenthal et al who were able to complete both cycles. These figures were not statistically different (P ¼ 0.23). There were also no significant statistical differences in the probability and 95% CI for EFS at 1 year between the patients completing only one cycle of treatment or both cycles, 0.29 (0.04, 0.61) and 0.54 (0.25, 0.76), respectively (P ¼ 0.29). The EFS for the two groups is shown in Figure 2 . Six patients had PAD defined as multiorgan metastases with or without bulky disease. Fourteen patients had recurrent metastatic disease (RD). The 1-year OS and 95% CI were 0.83 (0.27, 0.97) for the six patients with PAD, and 0.50 (0.23, 0.72) for 14 patients with recurrent disease (P ¼ 0.21 by log-rank test). The 1-year EFS rates and 95% CI were 0.67 (0.19, 0.90) for six patients with primary disease, and 0.36 (0.13, 0.59) for 14 patients with recurrent disease (P ¼ 0.18). Four of the patients with PAD are alive.
In this group, two patients who attained complete clinical response are alive 69 months and 50 months post transplant, respectively. The results are shown in Figure 3 .
Discussion
Ewing family of tumors comprises 16% of primary malignant bone tumors, with a peak age incidence between 10 and 25 years. This tumor is chemosensitive, and multimodal therapy has significantly improved outcome for patients with EFT (3-year survival rates 55-80%). [6] [7] [8] [9] [10] Despite these encouraging results, subgroups of patients who have a poor prognosis can be identified (survival of 10-30% at 3 years). Poor prognostic features at initial presentation include metastatic disease, particularly those with bone or BM involvement, bulky disease (48 cm diameter) at diagnosis, primary tumor involving axial (pelvic) or proximal (femur and humerus), shorter interval of EFS between diagnosis and relapse 6 and age older than 16 years. 11 Patients with exclusive lung metastases have a better prognosis than patients who have bone metastases (with or without lung metastases). In a large study, the 5-year EFS was 29% for patients with lung metastases, 19% for bone metastases and 8% for those with combined lung and bone metastases (Po0.001). 1 Despite the low probability of cure, patients with poor prognostic features do have chemoresponsive tumors, as indicated by in vitro data showing a steep dose-response relationship for EFT cell lines treated with a variety of chemotherapeutic Table 4 Toxicities in 20 patients during the first 100 days of post transplant Tandem autotransplant form Ewing's sarcoma J Rosenthal et al agents, 5 especially alkylating agents, platinum agents and epidophylotoxins. Intensification of therapy (both dose and timing) is critical to disease response. A high initial response rate and prolongation of progression-free interval are documented by several groups with the addition of etoposide and ifosfamide to the standard chemotherapy regimen. 9, [12] [13] [14] [15] [16] However, even with the most aggressive chemotherapy regimens, the long-term survival in patients with metastatic EFT is around 20%. 9, 17 The initial doselimiting toxicity for these agents is myeloablation. HSCT rescue overcomes this dose-limiting toxicity and allows dose escalation, sometimes by as much as 4-to 10-fold over maximal tolerated nonmyeloablative doses. On the basis of the observed steep dose-response curves in vitro, aggressive approaches, consisting of HDT followed by HSCT, have been utilized, using either fractionated TBI plus chemotherapy 8, [18] [19] [20] or chemotherapy alone. 11, [21] [22] [23] [24] [25] [26] In early studies carried out at the National Cancer Institute , using higher than standard doses of chemotherapy followed by TBI (8 Gy), the EFS rate declines from 30 to 40% at 3 years and 8, 19 to 10% at 6 years. 20 The investigators conclude that patients with poor prognosis ES treated with TBI and autologous BMT were able to achieve CR; however, this study failed to show any survival benefit over nontransplant. 20 Meyers et al. 27 reported results of a multiinstitutional study with Mel, etoposide and TBI followed by autologous HSCT in patients with advanced EFT. Twenty-three of 32 eligible patients proceeded with HDT and HSCT. The 2-year EFS for all eligible patients was 20%. A 24% 2-year post-HSCT EFS was reported for the subset of patients who received consolidation therapy. The investigators concluded that TBI followed by autologous hematopoietic stem cell reconstitution for high-risk EFT did not improve prognosis. On the other hand, multiple reports, mostly from Europe, have documented the beneficial effect of HDT followed by HSCT in patients with EFT. Gratwohl et al. 28 have reported on behalf of the Accreditation Committee, European Group for Blood and Marrow Transplantation, the Working Party on Pediatric Diseases and the Working party on Solid Tumors that the number of transplants for EFT in Europe increased from 44 in 1991 to 261 in 2002 for a total of 1896 transplants throughout that period. A variety of myeloablative regimens without TBI followed by HSCT for advanced EFT have been used. Early exploratory studies with HDT followed by HSCT documented activity against refractory, large localized and disseminated EFT. 4, 11, 22 Mel has long been the most commonly used agent in HDT regimen for advanced, high-risk EFT. The French Society for Pediatric Oncology has reported excellent results in children with poor prognosis EFT who were treated with BU (600 mg/ m 2 /dose four times a day Â 4 days) and Mel (140 mg/m 2 , given as 70 mg/m 2 /day Â 2 days). 23, 29 Thirty-four patients treated on this protocol had a 52% disease-free survival rate at 3 years. The pediatric BM transplant team from the University of Madrid reported an EFS rate of 55% at 4 years in a group of children and young adults with highrisk solid tumors that included 15 patients with EFT treated with BU at a dose of 16 mg/kg and Mel at a dose of 140 mg/m 2 followed by HSCT. 30 Similarly, the pediatric oncology group from the Royal Marsden Hospital in the United Kingdom used high-dose BU and Mel to treat a group of 18 patients with high-risk ES (including 11 patients with metastatic disease at presentation) and reported 13 out of 18 patients alive and disease free after a median follow-up of 2 years. 23 The decision to change our HDT regimen to Mel/BU was based on these studies. Further confirmation for this approach has been recently reported by the French Society for Pediatric Oncology. This group reported the outcomes in 97 patients with advanced EFT. Seventy-five of the patients achieved complete or very good PR and proceeded to treatment with the combination of Mel/BU followed by autologous HSCT rescue. The 5-year EFS and OS rates for all 97 patients were 37 and 38%, respectively. The EFS after HDC and HSCT was 47%. 31 The strategy of utilizing tandem high-dose therapy cycles has been tested in a number of refractory solid tumors in childhood, including neuroblastoma, lymphoma, ES and rhabdomyosarcoma. 21, 32 Grupp et al. 33 reported results of a study on 55 patients with advanced stage neuroblastoma. These patients have received a total of 94 HDT cycles on a tandem HDT protocol. Fifty-one out of 55 eligible patients have received both cycles. There were four (7%) toxic deaths. An estimated 3-year EFS of 58% was reported. 33 Adams et al. 34 have conducted their study on 28 pediatric patients with metastatic sarcoma, including 16 patients with ES. All 28 patients have been treated on a rapid sequence tandem HDT protocol. 26, 34 Twenty-four out of 28 patients were able to receive both cycles. Estimated 2-year EFS of 56% was reported. These data suggest that tandem high-dose therapy cycles are associated with acceptable mortality risks and may be effective in terms of reduction of relapse rate, increase of OS rate and disease-free survival rate.
In a recent report, Burdach et al. 25 concluded that tandem SCT is a feasible approach with acceptable toxicity that may offer a decent, although still not satisfactory, rate of long-term remission in most advanced EFT. Our results are similar to those presented by the Minnesota group. A group of 36 children and young adults with a variety of solid tumors had HDT followed by HSCT. The OS for 1 year and 3 years were 63 and 33%, respectively. Patients with a diagnosis of EFT or desmoplastic small round cell tumor had significantly better survival than those with other diagnoses with an estimated 3-year OS of 54% (95% CI: 29-79%) for this group of patients (P ¼ 0.03). 26 Kletzel et al. 35, 36 reported that tandem HSCT for patients with EFT and even triple HSCT in patients with neuroblastoma are feasible and have the potential of improving survival for some patients with high-risk EFT or neuroblastoma.
As the treatment-related mortality with HDT is rare, occurring in less than 5% of patients, we hypothesized that the intensity of treatment could be further escalated by the addition of a second cycle of HDT upon recovery from the first cycle. The morbidity and mortality associated with tandem cycles of HDT are yet unknown; however, they are likely to be greater than that associated with a single cycle, and this may offset the therapeutic advantages of tandem cycles. Our intention, in this retrospectively designed study, was to assess the feasibility and safety of two consecutive cycles of HDT followed by autologous HSCT in patients with poor prognosis EFT. The treatment, though aggressive, was well tolerated with acceptable toxicity and 5% TRM that occurred in one patient after the second course of HDT with HSCT. The TRM is similar to that reported in large collaborative group reports employing a single course of HDT and HSCT. 9, 17 This series adds to the growing body of data suggesting that HDT followed by HSCT may improve the outcome in a selected group of patients. With a median follow-up of 2.4 years, only one disease-related event occurred in a patient who survived longer than 1 year. The rates of OS and EFS for the entire group compare favorably with historically published data with conventional therapy and may suggest a role for HDT and HSCT in patients who have chemosensitive disease either at presentation (PAD) or after recurrence (RD). The role of two cycles of HDT followed by HSCT is yet undefined. Although only 50% of the patients with RD were able to proceed with the second course of HDT and HSCT, all patients with PAD were able to do so. The number of patients enrolled was too limited to demonstrate significant differences; however, the observed outcomes for these two distinctive groups of patients deserve further evaluation in a larger group of patients.
Our data add to the body of data suggesting that patients in a clinical and radiological CR who had consolidation with HDT followed by autologous HSCT have superior outcomes compared to those transplanted in PR.
In summary, our experience demonstrates that an alkylating agent-based HDT had acceptable toxicities despite previous aggressive therapy in selected patients with high-risk EFT. Patients with advanced primary EFT had better than expected survival compared to historical data with chemotherapy alone. 17 The number of patients in this report was too small to show statistically significant differences in outcome between patients with recurrent disease and patients with primary advanced EFT. We suggest that the favorable outcome in the latter group justifies the need for larger prospective trials examining the role of HDT followed by HSCT as an integral part of the primary therapy before the recurrence occurs. Only 65% of the patients were able to proceed to a second cycle of treatment, mostly due to disease recurrence in the interval between the two courses. Prospectively designed studies are needed for evaluation of the optimal approach for HDT followed by HSCT; primarily, double or even triple 36 cycles vs augmentation of a single cycle.
